Full Description
The ESC Textbook of Thrombosis is the third iteration of Therapeutic Advances in Thrombosis. Now a new addition to the European Society of Cardiology (ESC) publications portfolio, it is informed by the work of the ESC's Working Group on Thrombosis.
Written by internationally renowned experts in the field of thrombosis, the textbook presents an up-to-date and in-depth review of all aspects of thrombosis and antithrombotic therapies. Not only does it reflect contemporary European guidelines from the ESC but also it also summarizes the latest evidence from clinical trials.
Covering the topic in great detail with thirty-one chapters, the textbook is split into four sections: Pathophysiology of thrombosis, Clinical pharmacology of antithrombotic drugs, Therapeutic strategies, and Special situations.
Appealing to the large community of cardiovascular healthcare specialists in Europe and across the world, the textbook is a must read for cardiologists dealing with acute and chronic coronary syndromes, atrial fibrillation, artificial heart valves and pulmonary embolism. It will also appeal to cardiac surgeons, cardiovascular researchers, and general physicians alike.
Contents
1: Raffaele De Caterina, David J. Moliterno, and Steen Dalby Kristensen: Introduction
Section 1: Pathophysiology of thrombosis
2: Lina Badimon and Gemma Vilahur: Arterial thrombosis: Pathophysiological background
3: Marcello Di Nisio, Nicola Potere, Harry R. Buller, and Nick van Es: Venous thrombosis and thromboembolism: Pathophysiological background
4: Peter Calvert, Nicola Tidbury, and Gregory Y. H. Lip: Thrombosis & thromboembolism in atrial fibrillation: Pathophysiological background
5: Tobias Geisler: Thrombosis on foreign surfaces and devices
Section 2: Clinical pharmacology of antithrombotic drugs
6: Carlo Patrono and Bianca Rocca: Aspirin
7: Manan Pareek and Deepak L. Bhatt: Platelet P2Y12 inhibitors
8: Luis Ortega-Paz and Dominick Angiolillo: Dipyridamole, cilostazol, GP IIb/IIIa inhibitors, and PAR-1 antagonists
9: Renske Olie and Hugo ten Cate: Heparins, fondaparinux, hirudin, bivalirudin, argatroban and danaparoid
10: Freek W.A. Verheugt and Marc Brouwer: Vitamin K antagonists
11: Alex Benz and Stefan Hohnloser: Dabigatran
12: Lars C. Wallentin, Agneta Siegbahn, Peter Svensson, and Hakan Wallen: Oral factor Xa (FXa) inhibitors
13: James C. Fredenburgh and Jeffrey I. Weitz: Forthcoming oral factor XIa and FXIIa inhibitors
14: Peter R Sinnaeve and Frans Van de Werf: Thrombolytic therapy and ancillary antithrombotic therapies
Section 3: Therapeutic strategies
15: Raffaele De Caterina, Paul M Ridker, and Erica Michelotti: Antithrombotic strategies in primary cardiovascular prevention
16: Antonio Greco and Davide Capodanno: Antithrombotic strategies in patients undergoing elective percutaneous coronary interventions and in chronic coronary syndromes without interventions
17: William A. E. Parker, Raffaele De Caterina, David J. Moliterno, Steen Dalby Kristensen and Robert F. Storey: Antithrombotic therapy in ST-elevation acute myocardial infarction and non-ST elevation acute coronary syndromes
18: Naoki Misumida, Mohamad Alkhouli, and David J. Moliterno: Anti-thrombotic therapy for patients with prosthetic valves and during structural percutaneous interventions
19: Hans Christoph Diener, Graeme J. Hankey, and John W. Eikelboom: Antithrombotic therapies in ischaemic stroke
20: Jens Erik Nielsen-Kudsk, Kasper Korsholm, Asger Andersen, and Erik Lerkevang Grove: Antithrombotic therapy in patients with patent foramen ovale (PFO), PFO closure, left ventricular mural thrombus, atrial thrombus, and catheter-related thrombosis
21: Raffaele De Caterina and Rossella Marcucci: Atrial fibrillation: current and forthcoming antithrombotic therapies
22: Chaozer Er, Walter Ageno, and Ander Cohen: Venous thromboembolism: prophylaxis and treatment
23: Lars C. Wallentin, Ziad Hijazi, Gorav Bartra, and Johan Lindbäck: Biomarker-based risk stratification in cardiovascular disease
Section 4: Special situations
24: Vittorio Pengo and Gentian Denas: Antithrombotic therapies in inherited or acquired thrombophilia
25: Roxana Mehran, Alessandro Spirito, George Dangas, and David Cao: Prevention and treatment of bleeding related to antithrombotic drug treatment
26: Michael Maeng, Steen Dalby Kristensen, and Jolanta M. Siller-Matula: Management of patients treated with antithrombotic drugs undergoing surgery
27: Alexander C Fanaroff, Renato D Lopes, John H Alexander: Antithrombotic therapy in patients with atrial fibrillation and recent coronary stenting, with or without an acute coronary syndrome
28: Stefan Agewall, Vanessa Roldán, and Francisco Marín: Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, renal insufficiency, thrombophilia and pregnancy
29: Steven P. Dunn, Craig J. Beavers, and David J. Moliterno: Antithrombotic agents and drug-drug interactions
30: Jur ten Berg, Dirk Sibbning, Wout W.A. van den Broek, and Konstantinos D. Rizas: Personalised antithrombotic therapy: Measuring individual variation and monitoring
31: Serge Korjian, Yazan Daaboul, and C. Michael Gibson: Drug development, clinical trials, and regulatory requirements
